Cargando…

Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering

Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanz, Alessandra M., Chartrand, Esther, Eisenlohr, Claudia P., Lanz, Miguel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876381/
https://www.ncbi.nlm.nih.gov/pubmed/35214677
http://dx.doi.org/10.3390/vaccines10020219
_version_ 1784658157024313344
author Lanz, Alessandra M.
Chartrand, Esther
Eisenlohr, Claudia P.
Lanz, Miguel J.
author_facet Lanz, Alessandra M.
Chartrand, Esther
Eisenlohr, Claudia P.
Lanz, Miguel J.
author_sort Lanz, Alessandra M.
collection PubMed
description Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean age 43 (±21) years, with a history of CC-asthma and history of ≥2 exacerbations/year requiring systemic steroids and/or antibiotics. All had decreased Streptococcus pneumoniae antibody titers, with a mean average of 3 of 23 normal serotypes and were subsequently vaccinated with PPSV-23. Pre- and post-12-month vaccination questionnaires were administered, and 35 (54%) reported both decreased CC symptoms and asthma medication use. Baseline comparisons to those with no change in CC symptoms or asthma medication use revealed significantly lower exhaled nitric oxide (FeNO) levels (17 ± 10; 62 + 40 ppb), serum eosinophils (192 ± 156; 280 ± 166/mcL), and total IgE (132 ± 167; 275 ± 290 IU/mL) in those with improvement post-vaccination. Higher baseline symptoms scores for upper respiratory infections as a trigger to their CC (* p > 0.05) were found in those responding to PPSV-23. These data reveal a subset of asthma in younger adults, <65 years, with significantly decreased S. pneumoniae antibody titers with less CC symptoms and asthma medication use for exacerbations after PPSV-23 vaccination.
format Online
Article
Text
id pubmed-8876381
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88763812022-02-26 Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering Lanz, Alessandra M. Chartrand, Esther Eisenlohr, Claudia P. Lanz, Miguel J. Vaccines (Basel) Communication Symptoms of chronic cough (CC) from the airways are commonly treated with antibiotics, antitussives, bronchodilators, and steroids. There is a wide variability in treatment response, dependent on the exact cough etiology. Our case-series study was composed of 71 nonsmoking adults, 59 females, mean age 43 (±21) years, with a history of CC-asthma and history of ≥2 exacerbations/year requiring systemic steroids and/or antibiotics. All had decreased Streptococcus pneumoniae antibody titers, with a mean average of 3 of 23 normal serotypes and were subsequently vaccinated with PPSV-23. Pre- and post-12-month vaccination questionnaires were administered, and 35 (54%) reported both decreased CC symptoms and asthma medication use. Baseline comparisons to those with no change in CC symptoms or asthma medication use revealed significantly lower exhaled nitric oxide (FeNO) levels (17 ± 10; 62 + 40 ppb), serum eosinophils (192 ± 156; 280 ± 166/mcL), and total IgE (132 ± 167; 275 ± 290 IU/mL) in those with improvement post-vaccination. Higher baseline symptoms scores for upper respiratory infections as a trigger to their CC (* p > 0.05) were found in those responding to PPSV-23. These data reveal a subset of asthma in younger adults, <65 years, with significantly decreased S. pneumoniae antibody titers with less CC symptoms and asthma medication use for exacerbations after PPSV-23 vaccination. MDPI 2022-01-30 /pmc/articles/PMC8876381/ /pubmed/35214677 http://dx.doi.org/10.3390/vaccines10020219 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Lanz, Alessandra M.
Chartrand, Esther
Eisenlohr, Claudia P.
Lanz, Miguel J.
Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
title Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
title_full Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
title_fullStr Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
title_full_unstemmed Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
title_short Can PPSV-23 Vaccine Impact Exacerbations of Chronic Cough Symptoms and Medication Use in Younger Adult Asthmatics? A Clinical Question That Needs Answering
title_sort can ppsv-23 vaccine impact exacerbations of chronic cough symptoms and medication use in younger adult asthmatics? a clinical question that needs answering
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876381/
https://www.ncbi.nlm.nih.gov/pubmed/35214677
http://dx.doi.org/10.3390/vaccines10020219
work_keys_str_mv AT lanzalessandram canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering
AT chartrandesther canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering
AT eisenlohrclaudiap canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering
AT lanzmiguelj canppsv23vaccineimpactexacerbationsofchroniccoughsymptomsandmedicationuseinyoungeradultasthmaticsaclinicalquestionthatneedsanswering